Both GN Hearing and Demant lost shares in the Veteran Affairs (VA) sales channel to competitors in April.
This was revealed in the delayed monthly report published by the public sales channel, DNB analyst Rune Majlund Dahl tells Ritzau Finans.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.